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ABSTRACT
The adoptive transfer of donor CD4CD25 regulatory T cells has been shown to protect from lethal
graft-versus-host disease after allogeneic bone marrow transplantation in murine disease models. Efficient
isolation strategies that comply with good manufacturing practice (GMP) guidelines are prerequisites for the
clinical application of human CD4CD25 regulatory T cells. Here we describe the isolation of CD4CD25
T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-
separation protocol performed under GMP conditions. The generated cell products contained on average
49.5% CD4CD25high T cells that phenotypically and functionally represented natural CD4CD25 regula-
tory T cells and showed a suppressive activity comparable to that of CD4CD25 regulatory T-cell prepara-
tions purified by non–GMP-approved fluorescence-activated cell sorting.
© 2006 American Society for Blood and Marrow Transplantation
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Murine CD4CD25 regulatory T (Treg) cells do
ot induce graft-versus-host disease (GVHD), even
hen transplanted in large numbers and across com-
lete major histocompatibility complex barriers, but
uppress GVHD induced by CD25 T cells when
otransplanted at high ratios (1:1 or 1:2) [1-6]. T cells
ith similar phenotypic and functional characteristics
n vitro have also been identiﬁed in human cord and
dult peripheral blood, as well as in lymphoid organs
7-13]. Like their murine counterparts, they are
D4 and constitutively express intracellular cyto-
oxic T-lymphocyte antigen (CTLA)–4 and the tran-
cription factor forkhead box P3 (FOXP3), a key reg-
latory gene for the development and function of
atural Treg cells in mice and humans [14-16]. In
ontrast to murine Treg cells, human Treg cells seem
o reside predominantly in the subpopulation with t
B & M Tigh-level expression of CD25 and less so in the
ubpopulation with intermediate CD25 expression,
hich also contains memory and recently activated
cells [7,17,18]. In vitro, CD4CD25 Treg cells
uppress the proliferation of CD4 and CD8 T
ells after polyclonal or allogeneic stimulation in a
ell contact–dependent and cytokine-independent
anner [7,9,18]. On the basis of these similarities
etween human and mouse Treg cells, the adoptive
ransfer of donor CD4CD25 Treg cells after al-
ogeneic stem cell transplantation (SCT) is antici-
ated to be beneﬁcial for GVHD prophylaxis in
umans. A prerequisite for the evaluation of this
ypothesis in clinical trials is the development of
ell-separation strategies for the efﬁcient and reli-
ble enrichment of this rare cell population from
eripheral blood that comply with good manufac-
uring practice (GMP) guidelines. In this article, we
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2emonstrate that CD4CD25 Treg cells can be
solated under GMP conditions from standard leu-
apheresis products by magnetic cell-separation
echnologies. A detailed phenotypic and functional
omparison with ﬂuorescence-activated cell sorting
FACS)–puriﬁed CD4 T-cell subpopulations con-
rmed the preferential enrichment of natural Treg cells
ithin the generated cell products.
ATERIALS AND METHODS
ntibodies and Flow Cytometry (FACS)
FACS analysis was performed as published previ-
usly [18], with the following modiﬁcations. For analysis
f CD25 expression after magnetic cell separation, anti-
uman CD25-biotin (M-T321; Miltenyi Biotec, Ber-
isch Gladbach, Germany) followed by phycoerythrin
PE)–labeled or allophycocyanin (APC)–labeled anti-bi-
tin antibody (Bio3-18E7; Miltenyi Biotec) was used
o enhance ﬂuorescence intensity (directly PE- or
PC-conjugated antibodies did not allow sufﬁcient
ifferentiation of CD25high and CD25int cells as a
esult of competition with attached beads; Figure 1A).
ACS sorts were performed on a FACSAria (Becton
ickinson, Heidelberg, Germany). Sort gates for
igure 1. Efﬁcient enrichment of CD4CD25highFOXP3 T cel
onditions. A, A standard leukapheresis product (No. 6 from Tabl
ractions as detailed in the “Materials and Methods” section. At eac
how the initial leukapheresis product (left panel), the staining patter
eads (second panel), the CD25-enriched target cell fraction (third p
rom the leukapheresis product (left panel), the target cell fractio
ermeabilized, and stained for FOXP3. Plots are gated on CD4 T cells
68D4CD25high T cells were set as previously de-
cribed [18] and included CD4 T cells with higher
D25 expression levels than CD4CD25 cells within
eripheral blood mononuclear cells (PBMCs). Sort gates
or CD4CD25int T cells included CD4CD25 T
ells that did not reach the high CD25 expression level
equired for classiﬁcation as CD4CD25high T cells. All
orted subpopulations were97% pure upon reanalysis.
xpression of FOXP3 on a single cell level was analyzed
y using the PE anti-human Foxp3 staining set (clone
CH101; eBioscience, San Diego, CA) according to the
anufacturer’s instructions. PE-conjugated monoclonal
at immunoglobulin G2a (R35-95; BD Pharmingen,
an Diego, CA) was used as an isotype control.
agnetic Cell Separation
Leukapheresis products were obtained from 6 dif-
erent volunteers after their informed consent and in
ccordance with approved protocols. For all magnetic
ell separations, clinical-grade reagents were used, and
of 6 were performed in a certiﬁed GMP unit. Cells
ere washed and adjusted to 95 mL in phosphate-
uffered saline (PBS), ethylenediaminetetraacetic acid
EDTA), and 2% human albumin (HA), labeled with
.5 mL of CliniMACS CD19 MicroBeads (Miltenyi
leukapheresis products by magnetic cell separation under GMP
s depleted of B cells and separated into CD25 and CD25 cell
f the procedure, aliquots were taken and analyzed by FACS. Plots
e cells after B-cell depletion and incubation with anti-human CD25
and the CD25-depleted negative cell fraction (right panel). B, Cells
le panel), and the negative cell fraction (right panel) were ﬁxed,ls from
e 1) wa
h step o
n of th
anel),
n (midd
within the respective cell populations.
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CD4CD25 Regulatory T Cells
Biotec) for 30 minutes at room temperature on an
rbital shaker, washed again, and resuspended in 100
L of PBS/EDTA/2% HA. B cells were depleted
ith the CliniMACSplus instrument by using a LS
ubing set and the depletion program 2.1 (all Miltenyi
iotec). B cell–depleted cells were suspended in 190
L of PBS/EDTA/2% HA, labeled with 7.5 mL of
liniMACS CD25 MicroBeads for 30 minutes at
oom temperature on an orbital shaker, washed, and
esuspended in 100 mL. CD25 cells were isolated by
automatic cycles of positive selection by using the
nrichment program 3.1 of the CliniMACS device.
liquots before and after each staining, depletion, or
nrichment step were taken for FACS analysis.
roliferation and Suppression Assays
Polyclonal proliferation was determined in cultures
f 5  104 T cells (CD4 responder T cells [Tresp]
solated from the CD19/CD25-depleted cell fraction
ith anti-CD4 MicroBeads [Miltenyi Biotec], Clini-
ACS-puriﬁed CD4CD25 T cells, or FACS-puri-
ed CD4CD25high, CD4CD25int, or CD4CD25
cells) that were stimulated with 100 ng/mL anti-
D3 (OKT3; kind gift from Ortho Biotech, Neuss,
ermany) in the presence of 5  104 irradiated (30
y) autologous PBMCs in 96-well U-bottom plates in
00 L of RPMI 1640 medium supplemented with
0% fetal calf serum (Seromed, Berlin, Germany), 2
mol/L glutamine, 10 mmol/L N-2-hydroxyeth-
lpiperazine-N-2-ethanesulfonic acid, 1% nonessen-
ial amino acids (all PAN Biotech, Aidenbach, Ger-
any), 50 U/mL penicillin, 50 g/mL streptomycin,
nd 5  105 mol/L 2-mercaptoethanol (all Gibco
RL, Karlsruhe, Germany). To determine their sup-
ressive activity, titrated numbers of CliniMACS-pu-
iﬁed CD4CD25 T cells or FACS-puriﬁed
D4CD25high, CD4CD25int, or CD4CD25T cells
ere added to cultures of 5  104 Tresp cells to obtain
he indicated ratios and stimulated with 100 ng/mL
nti-CD3 in the presence of autologous antigen-pre-
enting cells. All cultures were incubated for 4 days
nd labeled with 18.5 MBq per well 3H-thymidine
Hartmann Analytics, Braunschweig, Germany) for
he last 18 hours. The 3H-thymidine incorporation
as measured by liquid scintillation counting (Top
ount; Perkin Elmer, Rodgau-Jügesheim, Germany).
ll assays were performed in triplicate. Suppression
as calculated by the following formula:
[1 (cpm(Tresp  Treg) ⁄ cpm Tresp alone)] 100.
OXP3 Quantitative Real-Time Polymerase Chain
eaction and Western Blotting
Total RNA from 2  105 cells was extracted by
sing the RNeasy Micro kit (Qiagen, Hilden, Ger-
any), and complementary DNA was synthesized by
sing the Reverse Transcription System (A3500; Pro- (
B & M Tega, Mannheim, Germany) with oligo(dT)15 prim-
rs. Reverse transcriptase-polymerase chain reaction
PCR) was performed by using previously described
rimers for FOXP3 and glyceraldehyde-3-phosphate
ehydrogenase [15], the QuantiTect SYBR Green
CR Kit (Qiagen), and Lightcycler 2.0 (Roche, Mann-
eim, Germany). For immunoblotting, lysates from 2
05 cells were separated in 10% sodium dodecylsulfate-
olyacrylamide gel electrophoresis gels and transferred
o polyvinylidene diﬂuoride membranes (Millipore,
chwalbach, Germany). Polyclonal goat anti-human
OXP3 (Abcam, Cambridge, UK) and horseradish per-
xidase–labeled rabbit anti-goat immunoglobulin (Dako,
amburg, Germany) were used together with the ECL
etection system (Amersham, Freiburg, Germany). Blots
ere stripped and reprobed with polyclonal rabbit anti-
ctin (Sigma Aldrich Chemie GmbH, Taufkirchen, Ger-
any) and horseradish peroxidase–labeled goat anti-rab-
it immunoglobulin (Dako) for loading controls.
ESULTS
fficient Enrichment of CD4CD25highFOXP3
Cells by Magnetic Cell Separation under
MP Conditions
Human PBMCs comprise both CD4 and CD4
ells that coexpress CD25, and activated B cells rep-
esent the main constituent of the CD4CD25 cell
opulation. In laboratory-scale experiments using
agnetic bead separation, we determined that a pri-
ary depletion of CD19 B cells followed by 3 selec-
ion cycles for CD25 allows the preferential retention
f CD4CD25high T cells (as compared with CD4
cells that express low CD25 levels) in only 2 sepa-
ation steps (data not shown). To test whether this
solation strategy is suited for potential clinical trials,
e conducted a study with clinical-grade reagents com-
rising 6 cell separations from leukapheresis products of
ifferent donors, 1 of which was performed outside a
ertiﬁed GMP laboratory and all others in strict com-
liance with GMP guidelines. Summarized results
rom all 6 separations are shown in Table 1.
The initial leukapheresis products contained 4.4 to
5.8  109 nucleated cells. On average, 18.2% (range,
5.0%-21.5%) of the cells coexpressed CD4 and CD25,
nd on average 1.9% were CD4CD25high T cells
range, 1.1%-2.9%). After magnetic cell separation,
3 to 262  106 cells were recovered in the target cell
raction (average, 1.72% of the starting population;
ange, 0.89%-2.47%), which contained less than
.01% B cells, only 7.3% CD4 cells (range, 2.9%-
4.3%), most of which were CD8CD25 T cells
data not shown), and 92% CD4 T cells (range,
5.5%-96.0%). Only 0.5% of the isolated cells were
D4CD25 (range, 0.2%-1.1%), whereas 91.5%range, 85.2%-95.6%) of the cells expressed both
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2D4 and CD25. The target cell fractions were highly
nd preferentially enriched for CD4CD25high T
ells that constituted on average 49.5% (range,
0.3%-63.1%) of the isolated cells. The recovery of
D4CD25high T cells as calculated from their fre-
uencies in the initial leukapheresis products was
6.5% (range, 25%-66%).
Representative FACS data illustrating the prefer-
ntial retention of CD4CD25high T cells after the
epetitive magnetic enrichment for CD25-expressing
ells are depicted in Figure 1A. Within the leuka-
heresis product (left panel), CD4CD25high T cells
re identiﬁed not only by their high CD25 expression,
ut also by their slightly lower CD4 levels as com-
ared with CD4CD25int or CD4CD25 T cells.
fter B-cell depletion and incubation with anti-CD25
eads, the overall staining level for CD25 was de-
reased as a result of competition of the ﬂuorescence-
abeled antibody with the attached beads, but the
D25high population can still be clearly identiﬁed. In
ddition, the proportion of CD4CD25 cells was
educed because of the depletion of activated B cells
oexpressing CD25 (second panel). After 3 repetitive
nrichment cycles for CD25, an efﬁcient retention of
D4CD25high T cells in the target cell fraction was
chieved (third panel), whereas residual CD4CD25high
cells were almost undetectable within the CD25-
epleted negative cell fraction (right panel).
To verify the enrichment of Treg cells, leuka-
heresis products and target and CD25-depleted cell
ractions were analyzed on a single cell level for the
xpression of the Treg cell–speciﬁc transcription factor
OXP3. As depicted in Figure 1B, FOXP3 was pref-
rentially expressed by CD4CD25high T cells within
BMCs, whereas CD4 T cells with intermediate
D25 levels contained fewer FOXP3 cells and the
D4CD25 subpopulation contained almost none
left panel). As expected, the CD4 T cells obtained
able 1. Preferential Enrichment of CD4CD25high Treg Cells from L
ompliance with GMP Guidelines
Leukapheresis Product
Run No.
Cells
(109)
CD4 (%)
(CD25 CD25high
1 7.5 21.5 2.0
2 7.9 16.6 1.1
3 4.4 16.8 1.4
4 15.8 15.0 1.4
5 14.7 19.0 2.9
6 8.7 20.3 2.4
Average 18.2 1.9
ix consecutive leukapheresis products were analyzed before and afte
were performed according to GMP guidelines by using the Cli
depletion, followed by 3 cycles of CD25 enrichment. Data repre
cell processing (Cells) and the cellular composition (%) as detefter magnetic enrichment for CD25 were highly en- r
70iched in FOXP3 cells (Figure 1B, middle panel),
hereas CD25-depleted cells contained only very few
OXP3 cells (Figure 1B, right panel). In summary,
hese data document a more than 25-fold preferential
nrichment of CD4CD25highFOXP3 T cells from
eukapheresis products by this 2-step, GMP-comply-
ng isolation strategy.
henotypic and Functional Characteristics of Cells
solated by Magnetic Cell Separation under
MP Conditions
Apart from FOXP3, a constitutive, high expres-
ion of intracellular CTLA-4 represents another well-
ocumented characteristic of natural CD4CD25
reg cells that has also been suggested to contribute to
heir suppressive function [13]. Analysis of CD4 T
ells in the target cell fraction by ﬂow cytometry
evealed a biphasic expression pattern for intracellular
TLA-4, reﬂecting the uniformly high expression
ithin the CD4CD25high subpopulation versus the low
xpression in CD25int and CD25 T cells (Figure 2A).
To analyze the potential effect of CD4CD25int
OXP3CTLA-4low T cells on the functional activity of
he target cell product, we isolated CD25high, CD25int,
nd CD25 cells by high-speed FACS sorting from the
D4 T-cell populations in the CD25-enriched target
ell fraction and the CD25-depleted negative cell frac-
ion (Figure 2B), and compared their FOXP3 expression
evels, anergy, and suppressive capacity with those
f the corresponding unfractionated target cell
roduct. As anticipated from the phenotypic analy-
es shown in Figure 1B, the target cell product was
onsiderably enriched in FOXP3-expressing cells,
s determined on the messenger RNA level by quan-
itative real-time PCR and on the protein level by
estern blotting (Figure 2C and D, respectively).
urther subdivision of the target cell product by
ACS into CD4CD25high and CD4CD25int cells
resis Products after Magnetic Bead–Based Cell Isolation Performed in
Target Cell Fraction
CD4 (%)
CD4 (%)
CD25 CD25 CD25high
6.9 0.2 91.8 59.2
14.3 0.3 85.2 30.7
6.4 1.1 91.7 30.3
6.0 0.3 93.7 55.4
2.9 0.4 95.6 63.1
7.0 0.4 91.2 58.2
7.3 0.5 91.5 49.5
etic bead–based isolation of CD4CD25 T cells. Cell separations
Splus device. The isolation procedure comprised 1 cycle of CD19
solute cell numbers of the leukapheresis products before and after
by multicolor FACS.eukaphe
Cells
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Bnd FOXP3-low–expressing cell populations, respec-
ively. In contrast, neither the CD25-depleted cell
raction obtained by magnetic separation nor the
D4CD25 T cells isolated from this population
howed any substantial FOXP3 expression.
The functional characteristics of the target cell prod-
cts obtained by magnetic separation under GMP con-
itions and of CD4CD25high T cells FACS-puriﬁed
rom these products were surprisingly similar. Both
opulations showed a comparable hypoproliferative
esponse (anergy) after polyclonal stimulation, whereas
uriﬁed CD4CD25 T cells proliferated vigorously
nd CD4CD25int T cells proliferated at intermedi-
te levels (Figure 3A). In addition, the suppressive
apacity of the target cell product, as measured in
tandard suppression assays, was comparable to that
f FACS-puriﬁed CD4CD25high T cells, whereas
D4CD25int cells showed only moderate activity
nd CD4CD25 T cells showed no suppressive ac-
igure 2. CD4CD25 T cells isolated under GMP conditions sh
ubpopulations with distinct FOXP3 messenger RNA and prote
eukapheresis product under GMP conditions were analyzed for intr
he CD25-enriched target cell fraction (CD25) and the CD25-depl
D4CD25int (CD25int) T-cell subpopulations as deﬁned by the so
eanalysis of the CD25 expression levels of further FACS-puriﬁed
cells (CD25). Cells are from the same separation as in (A). C an
arget cell fraction (CD25) in comparison to CD25high, CD25int, a
espective cell fractions. Values in (C) represent means  SEM froivity (Figure 3B). In summary, cells isolated from w
B & M Teukapheresis products by this GMP-complying mag-
etic cell separation protocol were highly enriched in
D4 T cells with phenotypic and functional charac-
eristics of natural CD4CD25 Treg cells.
ISCUSSION
CD4CD25 Treg cells are pivotal for the induc-
ion and maintenance of self-tolerance during ontog-
ny and thereby protect from autoimmunity [19]. It is
herefore conceivable that their regeneration also con-
ributes to tolerance induction after allogeneic SCT
20,21]. In mouse models of allogeneic SCT, we and
thers have shown that their suppressive activity could
e exploited for protection from GVHD. Several of
hese studies conﬁrmed that donor CD4CD25Treg
ells themselves do not induce GVHD but protect
ecipients from GVHD induced by CD25 T cells
iphasic expression of CTLA-4 and can be further separated into 2
ls. A, Cell fractions obtained by magnetic cell separation of a
ar CTLA-4 expression. Histograms represent CD4 T cells within
gative cell fraction (CD25) or the CD4CD25high (CD25high) and
s used for further separation of the target cell fraction by FACS. B,
D25high (CD25high), CD4CD25int (CD25int), and CD4CD25
XP3 messenger RNA (C) and protein expression levels (D) of the
25CD4 T cells obtained by further FACS puriﬁcation from the
nsecutive isolations.ow a b
in leve
acellul
eted ne
rt gate
CD4C
d D, FO
nd CDhen cotransplanted in high numbers [1-3]. Depend-
271
i
u
t
G
T
i
t
t
E
t
t
d
l
G
B
C
s
A
m
b
s
f
d
a
f
o
p
w
e
w
t
d
d
o
E
e
f
u
p
t
C
s
c
c
t
e
t
w
i
(
p
c
w
t
p
g
c
f
n
c
F
t
w
p
s
b
F
u
a
s
f
f
C
e
w
r
M
f
(
r
m
s
c
t
t
P. Hoffmann et al.
2ng on the strain combinations and experimental set-
ps, protection ranged from reduced GVHD severity
o complete inhibition of clinical manifestations and
VHD-associated lethality. However, cotransplanted
reg cells did not induce an overall paralysis of the
mmune system, because both the graft-versus-hema-
opoiesis effect and the graft-versus-tumor effect of
ransplanted CD25 T cells were maintained [4,22].
ven their delayed transfusion ameliorated GVHD,
hus suggesting that Treg cells could also be adminis-
ered for the treatment of GVHD provided that the
igure 3. CD4CD25 T cells isolated by magnetic cell separation
nder GMP conditions are hypoproliferative and show suppressive
ctivity. CD4 T cells with high, intermediate, or negative expres-
ion levels for CD25 were puriﬁed by FACS from the target cell
raction and the negative cell fraction. A, Cells from the target cell
raction (CD25) or the various subpopulations (CD25high,
D25int, and CD25) were stimulated with anti-CD3 in the pres-
nce of autologous antigen-presenting cells for 4 days. Proliferation
as determined by 3H-thymidine incorporation and is shown in
elation to that of autologous CD4 Tresp cells (see “Materials and
ethods” for details). B, Autologous CD4 Tresp cells and cells
rom the target cell fraction (CD25) or the puriﬁed subpopulations
CD25high, CD25int, and CD25) were cocultured at the indicated
atios and stimulated as described in (A). Proliferation was deter-
ined by 3H-thymidine incorporation, and the percentage suppres-
ion was calculated by comparing the proliferative response in the
ocultures with cultures of Tresp cells alone, as described in “Ma-
erials and Methods.” All assays in (A) and (B) were performed in
riplicate. Data represent the means  SEM of all 6 isolations.isease course is not too aggressive [6]. C
72To test these ﬁndings in clinical trials, we estab-
ished an isolation strategy for human Treg cells under
MP conditions based on magnetic cell separation.
ecause of the lack of exclusive surface makers for
D4FOXP3 Treg cells, their constitutive expres-
ion of CD25 was used for magnetic enrichment.
lthough this approach has already been applied in
any laboratories for experimental purposes, it has
een unclear whether it would be suited for the large-
cale puriﬁcation of Treg cells under GMP conditions
or clinical applications. To this end, we sought to
evelop a strategy that ensures the efﬁcient and reli-
ble enrichment of human CD4CD25high T cells
rom leukapheresis products with a minimal number
f reagents and selection steps. The ﬁnal protocol
resented here comprises 1 cycle of B-cell depletion
ith anti-human CD19 beads followed by 3 repetitive
nrichment cycles for CD25 cells. B-cell depletion
as included to eliminate activated CD25 B cells
hat would contaminate Treg cell products to various
egrees, depending on the blood composition of the
onor. More importantly, we reasoned that depletion
f B cells from such products might reduce the risk of
pstein-Barr virus–associated lymphoproliferative dis-
ase in patients receiving Treg cells early after SCT. In
act, B cells were almost undetectable in the cell prod-
cts generated under GMP conditions, and the low
ercentage of CD4CD25 cells still present in the
arget cell fraction mainly consisted of activated
D8 T cells and a few natural killer cells (data not
hown). It was recently shown that a single magnetic
ell-separation step efﬁciently depletes human Treg
ells from leukapheresis products but is insufﬁcient for
heir enrichment [23]. In our protocol, the repetitive
nrichment for CD25 ensured the preferential reten-
ion of cells with high CD25 expression as compared
ith those with intermediate CD25 levels and resulted
n an almost-complete elimination of CD25 T cells
Figure 1A). Of note, the 3 positive selection cycles are
erformed in an automated fashion such that retained
ells are re-exposed to the magnet without additional
ashing or bead incubation steps that would prolong
he procedure and risk increased cell loss.
Recovery of CD4CD25high T cells from leuka-
heresis products was on average 46.5%, and the tar-
et cell products contained 63 to 262  106 cells, thus
linically relevant numbers for adoptive T-cell trans-
er studies. Because these cellular products contained
ot only CD4CD25high T cells, but also CD4 T
ells with intermediate CD25 expression levels, we
ACS-puriﬁed these subpopulations and examined
hem in detail. As expected, CD4CD25high T cells
ere uniformly positive for FOXP3 and CTLA-4 and
otently suppressed non-Treg cells in functional as-
ays. Although the molecular mechanisms responsi-
le for the potent suppressive activity of
D4CD25 Treg cells are still not identiﬁed, it is
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CD4CD25 Regulatory T Cells
Bow well established that FOXP3 expression is es-
ential for their thymic generation and peripheral
unction. A lack of function mutation in the FOXP3
ene results in the loss of CD4CD25 Treg cells
nd lethal autoimmunity in mice and humans, as
bserved in the scurfy mouse strain [14,16] and in
PEX (immune dysregulation, polyendocrinopathy,
nteropathy, X-linked) patients [24]. The
D4CD25int cell population was more heteroge-
eous than the CD4CD25high T cell population and
ontained FOXP3CTLA-4 Treg cells as well as
OXP3CTLA-4low memory and recently activated
cells (compare Figure 1B and 2A). In functional
ssays, these CD4CD25int T cells showed a less
ronounced but still substantial suppressive effect,
hus suggesting that the FOXP3 cells within this
ubpopulation indeed represent functional Treg cells.
ence, the frequency of Treg cells within the target
ell products is even higher than that deduced from
he quantiﬁcation of CD4CD25high T cells (Table 1;
igure 1). This might explain why magnetically en-
iched Treg cells and FACS-puriﬁed CD4
CD25high
cells show almost the same suppressive activity in a
tandard in vitro suppression assay (Figure 3). Because
rotection from GVHD in murine studies was ob-
erved when donor Treg cells were cotransplanted at
:1 or 1:2 ratios with non-Treg cells, we aimed at a
urity of at least 50% for FOXP3Treg cells when
eveloping our isolation strategy. As this goal was
chieved, we have now initiated a phase I clinical trial
xamining the adoptive transfer of donor Treg cells in
ecipients of allogeneic stem cell grafts. Such stud-
es aim to reduce the risk for GVHD after alloge-
eic SCT without completely abrogating the bene-
cial donor T-cell effects, such as immunity
o infection, facilitation of engraftment, and graft-
ersus-tumor activity.
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